Allan-Herndon-Dudley syndrome

Overview

Allan-Herndon-Dudley syndrome (AHDS) is a rare, inherited neurological disorder that primarily impacts males. It is characterised by severe intellectual disability and problems with movement, including weakness and spasticity (stiffness) of muscles [PMID:33678536]. The condition is caused by a disruption in thyroid hormone transport to the brain, which is crucial for normal brain development. Individuals with AHDS typically show symptoms from birth or early infancy.

The syndrome is named after the doctors who first described it in 1944. Due to its X-linked inheritance pattern, female carriers usually do not show severe symptoms, though some might experience milder learning difficulties or thyroid function changes [PMID:33678536].

Symptoms & clinical features

The symptoms of Allan-Herndon-Dudley syndrome can vary in severity but typically include a range of developmental and neurological challenges. Common features observed from infancy often include hypotonia (poor muscle tone), which can make feeding difficult and delay motor skills like sitting and walking [PMID:20301476]. As individuals get older, muscle spasticity and contractures (permanent tightening of muscles and tendons) can develop, further limiting movement.

Intellectual disability is a hallmark of AHDS, ranging from severe to profound. Affected individuals usually have very limited speech development, and cognitive functions are significantly impaired. Other symptoms may include microcephaly (a smaller head size), seizures, and developmental delays in reaching milestones such as head control, sitting, and walking. Some individuals may also have facial features that are considered distinctive.

Video: Genetics 101

Affected organs

Allan-Herndon-Dudley syndrome primarily affects the brain and the musculoskeletal system. The brain is profoundly impacted due to impaired thyroid hormone transport, leading to widespread neurological damage and severe intellectual disability. This also affects motor control centres, contributing to hypotonia and spasticity.

The musculoskeletal system is affected by neurological impairment, leading to muscle weakness, stiffness, and contractures, particularly in the limbs. These issues can result in difficulties with mobility and require ongoing physical therapy and supportive care.

Multiple body systems

Systemic involvement

Cellular impact

Mechanism at cellular level

Risks & severity

Allan-Herndon-Dudley syndrome is considered a severe condition with significant lifelong impact, predominantly in males. The onset of symptoms is typically observed in early infancy, often with hypotonia and developmental delay being the initial signs. The condition is progressive in terms of motor challenges, with spasticity and contractures often worsening over time.

The intellectual disability associated with AHDS is generally profound. Life expectancy can be reduced due to associated complications, such as respiratory infections, often linked to severe neurological impairment and feeding difficulties. Exact prevalence is not well established, but it is considered a rare disorder.

Genetic causes

Allan-Herndon-Dudley syndrome is caused by pathogenic variants in the SLC16A2 gene [PMID:20301476]. The SLC16A2 gene provides instructions for making a protein called MCT8 (monocarboxylate transporter 8). This protein plays a critical role in transporting thyroid hormones, specifically triiodothyronine (T3), across cell membranes, particularly in the brain.

Thyroid hormones are essential for normal neurological development and function. When the MCT8 protein is non-functional or works incorrectly due to a variant in the SLC16A2 gene, T3 cannot be efficiently transported into brain cells. This lack of T3 in brain tissue, despite potentially normal or even elevated levels in the blood, disrupts vital brain development and leads to the severe neurological symptoms characteristic of AHDS.

• SLC16A2
  solute carrier family 16 member 2
  The SLC16A2 gene provides instructions for a protein critical in transporting thyroid hormone into nerve cells, essential for proper nervous system development.

Inheritance pattern

Allan-Herndon-Dudley syndrome has an X-linked recessive inheritance pattern. This means the gene responsible, SLC16A2, is located on the X chromosome.

Males (who have one X and one Y chromosome) are primarily affected by the syndrome because they only have one copy of the SLC16A2 gene. If this copy carries a pathogenic variant, they will develop the condition. Females (who have two X chromosomes) can be carriers if one of their X chromosomes carries a pathogenic variant. They usually do not develop severe symptoms because their other, unaffected X chromosome can compensate. However, some female carriers may experience milder learning difficulties or subtle changes in thyroid hormone levels [PMID:33678536]. Each son of a carrier mother has a 50% chance of inheriting the pathogenic variant and developing the condition, while each daughter has a 50% chance of being a carrier.

Diagnosis & testing

Diagnosis of Allan-Herndon-Dudley syndrome is typically considered in male infants or young children presenting with severe developmental delay, hypotonia, and spasticity, particularly if accompanied by atypical thyroid function tests (high T3, normal/low T4, normal TSH) [PMID:20301476]. Genetic testing is used to confirm the diagnosis by identifying pathogenic variants in the SLC16A2 gene.

In the UK, genetic testing for suspected AHDS would typically be initiated following referral to a clinical geneticist or neurologist. The NHS Genomic Medicine Service (GMS) offers genomic testing for a range of rare conditions, including AHDS, through specific R-codes such as R146 (Intellectual disability - X-linked). A clinical genetics team or genetic counsellor would arrange appropriate testing and discuss the implications of the results.

Management & lifestyle

As there is no cure for Allan-Herndon-Dudley syndrome, management focuses on supportive care to address symptoms and improve quality of life. This usually involves a multidisciplinary team approach including paediatricians, neurologists, physiotherapists, occupational therapists, and speech and language therapists.

Physiotherapy and occupational therapy are crucial to help manage muscle tone, prevent contractures, and support mobility. Speech and language therapy can assist with feeding difficulties and communication strategies. Medical treatments may be used to manage symptoms such as seizures or severe spasticity. Nutritional support, sometimes with a feeding tube, may be necessary for those with significant feeding difficulties. Experimental treatments aimed at improving thyroid hormone transport to the brain are a subject of ongoing research, but are not standard clinical practice. Families are encouraged to engage with local support services and genetic counselling for ongoing care and information.

UK care pathway

In the UK, if Allan-Herndon-Dudley syndrome is suspected, the first step is typically a referral to a specialist, such as a paediatric neurologist or a clinical geneticist. These specialists can assess the individual, order appropriate investigations, and guide the diagnostic process.

Genetic testing for conditions like AHDS often falls under the remit of the NHS Genomic Medicine Service (GMS). Referral to the GMS for genomic testing, using services like the R-code for X-linked intellectual disability (R146), would be arranged by a clinical genetics team. Genetic counsellors play a vital role in providing information and support to families, explaining the inheritance pattern, and discussing the implications of a genetic diagnosis.

Related conditions

When considering neurological developmental disorders, several conditions might present with overlapping features with Allan-Herndon-Dudley syndrome. These can include other forms of X-linked intellectual disability, such as Fragile X syndrome, or conditions causing hypotonia and developmental delay, like some forms of cerebral palsy.

It is important to differentiate AHDS from other thyroid-related disorders, as its primary defect lies in thyroid hormone transport to the brain, rather than simple thyroid hormone production. A careful clinical evaluation and targeted genetic testing are essential to arrive at a precise diagnosis.

Frequently asked questions

References

1. Adam MP, Bick S, Mirzaa GM. Allan-Herndon-Dudley Syndrome. 1993. PMID: 20301789
2. Chakraborty S, Das D. Allan-Herndon-Dudley Syndrome. Indian journal of pediatrics. 2025. PMID: 40131620
3. Groeneweg S, van Geest FS, Peeters RP. Thyroid Hormone Transporters. Endocrine reviews. 2020. PMID: 31754699
4. Felmlee MA, Jones RS, Rodriguez-Cruz V. Monocarboxylate Transporters (SLC16): Function, Regulation, and Role in Health and Disease. Pharmacological reviews. 2020. PMID: 32144120
5. Verma S. Allan-Herndon-Dudley syndrome. Indian journal of pediatrics. 2008. PMID: 18589880
6. Masnada S, Sarret C, Antonello CE. Movement disorders in MCT8 deficiency/Allan-Herndon-Dudley Syndrome. Molecular genetics and metabolism. 2022. PMID: 34969638
7. Lamb YN. Tiratricol: First Approval. Drugs. 2025. PMID: 40549098
8. Wilpert NM, Hewitt AL, Pons R. Patients with Allan-Herndon-Dudley Syndrome (MCT8 Deficiency) Display Symptoms of Parkinsonism in Childhood and Respond to Levodopa/Carbidopa Treatment. Movement disorders : official journal of the Movement Disorder Society. 2025. PMID: 40088079